and which recruited β-arrestin with efficacy slightly less than ARM390 (which in our hands has an Emax on par with Leu-enkephalin) [14,17]. Thus, PN6047 shared similarity with the failed Adolor and Astra Zeneca compounds, looking promising in terms of preclinical in vivo effects, but ret...